Page 11 of 13
Immunogenicity and safety of measles-mumps-rubella vaccine delivered by disposable-syringe jet injector in India: A randomized, parallel group, non-inferiority trial
2018 Bavdekar, A
Tags: Live Attenuated, MMR, Other Viruses, Phase 4, Stratis
February 21, 2018
Phase I study of an active immunotherapy for asymptomatic phase Lymphoplasmacytic lymphoma with DNA vaccines encoding antigen-chemokine fusion: study protocol
2018 Thomas, SK
Tags: Cancer, DNA, Lymphoma, Phase 1, Tropis
February 13, 2018
Safety, tolerability, and immunogenicity of two Zika virus DNA vaccine candidates in healthy adults: randomised, open-label, phase 1 clinical trials
2018 Gaudinski, MR
Tags: Arboviruses, DNA, Improved Performance, Phase 1, Stratis
February 10, 2018
PharmaJet and Genexine collaborate on DNA vaccine development
GOLDEN, Colo. — Feb. 20, 2018 — PharmaJet®, the maker of innovative, needle-free injection technology, today announced a global license agreement with Genexine, a leading biotherapeutics company headquartered in South Korea, for the development and commercialization of DNA vaccines for human applications using the PharmaJet needle-free injection systems.
Tags: DNA, Nucleic Acid, Other, Tropis
February 2, 2018
Vaccibody Expands Human Clinical Trial of HPV Vaccine
GOLDEN, Colo. — Feb. 6, 2018 — PharmaJet, the maker of innovative, needle-free injection technology, today announced that Vaccibody AS is expanding their human clinical trial (phase IIa) for the study of a vaccine to treat HPV disease using the PharmaJet Stratis® needle-free injection system.
Tags: DNA, HPV, Nucleic Acid, Stratis
January 26, 2018
PharmaJet touts needle-free tech for polio vaccine administration
PharmaJet touted results today from a study evaluating its needle-free injection technology as a way to administer the poliovirus vaccine.
Study shows superiority of PharmaJet Needle-free Injector for poliovirus vaccine administration
GOLDEN, Colo. — Jan. 23, 2018 — PharmaJet® Inc., the maker of innovative, needle-free injection technology, announced that a study was published in Heliyon Journal showing PharmaJet needle-free injection is superior to needle and syringe for fractional dose poliovirus vaccine campaigns.
January 9, 2018
Zika Virus vaccine shows significantly higher immune response with Needle-free delivery
GOLDEN, Colo. — Jan. 9, 2018 — PharmaJet, the maker of innovative, needle-free injection technology announced that a recently published study in The Lancet demonstrated that delivery of a Zika virus vaccine with the PharmaJet Stratis® Needle-free Jet injector produced a significantly higher immune response, as compared with administration via needle and syringe.
Tags: DNA, Nucleic Acid, Stratis, Zika
January 4, 2018
Success of mRNA Rabies Vaccine Human Study linked to Needle-free Injection
GOLDEN, Colo. – Dec. 5, 2017 – PharmaJet® Inc., the maker of needle-free injection technology, announced today that the first ever human clinical study of an mRNA rabies vaccine successfully showed immunogenicity when administered with their needle-free injection devices.
Tags: mRNA, Nucleic Acid, Rabies, Stratis, Tropis, Tropis/Stratis
November 7, 2017
Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial
2017 Alberer, M
Tags: Improved Performance, Other Viruses, Phase 1, Rabies, RNA, Stratis, Tropis, Tropis/Stratis
September 23, 2017
Feasibility of conducting intradermal vaccination campaign with inactivated poliovirus vaccine using Tropis intradermal needle free injection system, Karachi, Pakistan
2017 Yousafzai, MT
Tags: Inactivated, Polio, Tropis
September 18, 2017
InnoSTARS Hot, New U.S. Medical Tech Winner Exciting Shot to Arm
InnoSTARS crowned a hot, new medical technology winner delivering an exciting shot to the arm of the technology landscape with its breakthrough innovation gaining international attention.
Tags: Stratis, Tropis, Tropis/Stratis
August 18, 2017
Safety and immunogenicity of a modified vaccinia Ankara vaccine using three immunization schedules and two modes of delivery: A randomized clinical non-inferiority trial
2017 Jackson, LA
Tags: Live Attenuated, Other Viruses, Phase 2, Pox, Stratis
March 23, 2017
PharmaJet® partners with Serum Institute to Launch Needle-Free MMR Vaccine
GOLDEN, Colo. — Mar. 7, 2017 — PharmaJet, the maker of innovative, needle-free injection technology, announced its partnership with Serum Institute of India, the world’s largest vaccine manufacturer, is commercializing needle-free delivery of the MMR vaccine using the Stratis® 0.5mL needle-free injection system.
February 28, 2017
NIH Zika Vaccine Initial Trial Results Encouraging
Golden, Co. — Jan. 4 , 2017 — PharmaJet, the maker of innovative, needle-free injection technology, was featured on a CBS 60 Minutes segment concerning the National Institutes of Health DNA vaccine clinical trial for the Zika virus.
Tags: DNA, Nucleic Acid, Stratis, Zika
January 2, 2017
Antigen Targeting to Human HLA Class II Molecules Increases Efficacy of DNA Vaccination
2016 Grodeland, G
Tags: DNA, Improved Performance, Influenza, Pig, Respiratory Viruses, Tropis
November 1, 2016
Rapid development of a DNA vaccine for Zika virus
2016 | Dowd, K https://pubmed.ncbi.nlm.nih.gov/27708058/
Tags: Arboviruses, DNA, Non-Human Primate, Stratis, Zika
October 14, 2016
PharmaJet® and Vaccibody collaborate on HPV vaccine development
GOLDEN, Colo. — Oct. 25, 2016 — PharmaJet today announced a collaboration with Vaccibody AS to provide needle-free injection technology for the study of a vaccine to eradicate HPV. This disease is the main cause of cervical cancer affecting 530,000 women globally annually
Tags: DNA, HPV, Nucleic Acid, Stratis
October 7, 2016
PharmaJet® collaborates with World Health Organization
Golden, Co. — August 30, 2016 — PharmaJet today announced a multi-year agreement with the World Health Organization to provide PharmaJet’s Needle-free technology to be used in the global effort to eradicate polio.
The PharmaJet Tropis® Needle-free device has been proven to be safe, fast and easy-to-use with no possibility of needle re-use or needle sticks.
August 22, 2016
NIH using PharmaJet® in DNA Vaccine Clinical Trial for Zika Virus
Golden, Co. — August 3, 2016 — PharmaJet, the maker of innovative, needle-free injection technology, announced that the National Institutes of Health will use the PharmaJet Stratis® needle-free device in a DNA vaccine clinical trial for the Zika virus.
DNA vaccines are the way of the future. Unlike traditional vaccines, like for flu or measles, that contain whole viruses, DNA vaccines contain just a tiny piece of a virus’s genetic code, making them safe and easy to work with. For these vaccines to work however, it is not enough to just get into the bloodstream like a traditional injection, the DNA vaccine must get directly into the cells. For that purpose, a new delivery method was needed.
Tags: DNA, Nucleic Acid, Stratis, Zika
August 3, 2016
Page 11 of 13